BTIG Boosts OrthoPediatrics Price Target to $24

Analysts see upside potential for the medical device company focused on pediatric orthopedics.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Equity research firm BTIG Research has increased its price target for shares of OrthoPediatrics (NASDAQ:KIDS) from $23 to $24, maintaining a "buy" rating on the stock. The analysts cited the company's strong fourth-quarter financial results, which included a narrower-than-expected loss and slightly higher-than-projected revenue.

Why it matters

OrthoPediatrics is a leading provider of specialized medical devices for children with orthopedic conditions. The company's focus on this niche market has allowed it to develop innovative products and establish a strong market position. The increased price target from BTIG suggests analysts see further upside potential as OrthoPediatrics continues to execute on its growth strategy.

The details

In its research report, BTIG cited OrthoPediatrics' Q4 2025 results, which saw the company report a loss of $0.26 per share, beating the consensus estimate of a $0.37 per share loss. Revenue for the quarter came in at $61.61 million, slightly above the $61.27 million expected by analysts. The company also reiterated its full-year 2026 revenue guidance of $262 million to $266 million, in line with Wall Street's projections.

  • OrthoPediatrics reported Q4 2025 results on February 26, 2026.

The players

BTIG Research

An equity research firm that covers OrthoPediatrics and has increased its price target on the stock.

OrthoPediatrics

A medical device company focused exclusively on providing orthopedic solutions for children.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The increased price target from BTIG Research reflects analysts' confidence in OrthoPediatrics' ability to continue growing its business and capturing market share in the pediatric orthopedics space. The company's strong Q4 results and reiterated guidance suggest it is executing well on its strategic priorities.